High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.

A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis ...

Study to determine which treatments best for which inflammatory arthritis patients should result in patients being better ...

Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, ...

8 There is a consensus that csDMARDs are the mainstay of RA treatment, and the 2019 update of the EULAR recommendations supported the use of methotrexate as the first-line DMARD. 8 If there is ...

Leflunomide is the only nonbiologic DMARD developed specifically for the treatment of RA. It is an isoxazole derivative and its active metabolite, teriflunomide (formerly known as A77 1726), acts ...

RA treatment aims to decrease inflammation, which decreases symptoms (pain/discomfort and stiffness), and lessens the risk of joint damage. By limiting joint damage, disability is reduced. The primary ...

The risk for lung cancer is especially high among those with rheumatoid arthritis who also have interstitial lung disease.

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...